Prostate Cancer Theranostics - An Overview

Metastatic prostate cancer is incurable, and novel methods to detect the disease earlier and to direct definitive treatment are needed. Molecularly specific tools to localize diagnostic and cytotoxic radionuclide payloads to cancer cells and the surrounding microenvironment are recognized as a criti...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 10; p. 884
Main Authors Abou, Diane, Benabdallah, Nadia, Jiang, Wen, Peng, Lu, Zhang, Hanwen, Villmer, Alexandria, Longtine, Mark S., Thorek, Daniel L. J.
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 05.06.2020
Subjects
alpha particle
Oncology
peptide
prostate cancer
radionuclide
radiotherapy
Online AccessGet full text

Cover

Abstract Metastatic prostate cancer is incurable, and novel methods to detect the disease earlier and to direct definitive treatment are needed. Molecularly specific tools to localize diagnostic and cytotoxic radionuclide payloads to cancer cells and the surrounding microenvironment are recognized as a critical component of new approaches to combat this disease. The implementation of theranostic approaches to characterize and personalize patient management is beginning to be realized for prostate cancer patients. This review article summarized clinically translated approaches to detect, characterize, and treat disease in this rapidly expanding field.
AbstractList Metastatic prostate cancer is incurable, and novel methods to detect the disease earlier and to direct definitive treatment are needed. Molecularly specific tools to localize diagnostic and cytotoxic radionuclide payloads to cancer cells and the surrounding microenvironment are recognized as a critical component of new approaches to combat this disease. The implementation of theranostic approaches to characterize and personalize patient management is beginning to be realized for prostate cancer patients. This review article summarized clinically translated approaches to detect, characterize, and treat disease in this rapidly expanding field.
Author Peng, Lu
Longtine, Mark S.
Zhang, Hanwen
Villmer, Alexandria
Abou, Diane
Benabdallah, Nadia
Thorek, Daniel L. J.
Jiang, Wen
AuthorAffiliation 1 Department of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine , St. Louis, MO , United States
6 Oncologic Imaging Program, Siteman Cancer Center, Washington University School of Medicine , St. Louis, MO , United States
3 Radiology Cyclotron Facility, Mallinckrodt Institute of Radiology, Washington University in St. Louis , St. Louis, MO , United States
4 Department of Biomedical Engineering, Johns Hopkins University , Baltimore, MD , United States
5 Department of Biomedical Engineering, Washington University in St. Louis , St. Louis, MO , United States
2 Program in Quantitative Molecular Therapeutics, Washington University School of Medicine , St. Louis, MO , United States
AuthorAffiliation_xml – name: 2 Program in Quantitative Molecular Therapeutics, Washington University School of Medicine , St. Louis, MO , United States
– name: 6 Oncologic Imaging Program, Siteman Cancer Center, Washington University School of Medicine , St. Louis, MO , United States
– name: 5 Department of Biomedical Engineering, Washington University in St. Louis , St. Louis, MO , United States
– name: 3 Radiology Cyclotron Facility, Mallinckrodt Institute of Radiology, Washington University in St. Louis , St. Louis, MO , United States
– name: 4 Department of Biomedical Engineering, Johns Hopkins University , Baltimore, MD , United States
– name: 1 Department of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine , St. Louis, MO , United States
Author_xml – sequence: 1
  givenname: Diane
  surname: Abou
  fullname: Abou, Diane
– sequence: 2
  givenname: Nadia
  surname: Benabdallah
  fullname: Benabdallah, Nadia
– sequence: 3
  givenname: Wen
  surname: Jiang
  fullname: Jiang, Wen
– sequence: 4
  givenname: Lu
  surname: Peng
  fullname: Peng, Lu
– sequence: 5
  givenname: Hanwen
  surname: Zhang
  fullname: Zhang, Hanwen
– sequence: 6
  givenname: Alexandria
  surname: Villmer
  fullname: Villmer, Alexandria
– sequence: 7
  givenname: Mark S.
  surname: Longtine
  fullname: Longtine, Mark S.
– sequence: 8
  givenname: Daniel L. J.
  surname: Thorek
  fullname: Thorek, Daniel L. J.
BookMark eNpVkU1rHDEMhk1JaT6ac69zLIXZyLbG47kUwtI2gUB6SKE3o_FokgmzdmrPbum_rzcbSqOLhCQefbyn4ijEwEJ8kLDS2nYXYwx-pUDBCsBafCNOlNJYd6h_Hv0XH4vznB-hmGlAgn4njrVqrGoaOBGfvqeYF1q4WlPwnKq7B04USm7yuaqry1Dd7jjtJv79Xrwdac58_uLPxI-vX-7WV_XN7bfr9eVN7VGbpaYORujbAVpEOXZaEemh12XD0Qyq823rrTI9qOK0RQskidEwEoxGjqzPxPWBO0R6dE9p2lD64yJN7jkR072jVNab2VkGiwZ4aJoGy4FUvtGzRCNlj-XYwvp8YD1t-w0PnsOSaH4FfV0J04O7jzvXqg4UmgL4-AJI8deW8-I2U_Y8zxQ4brNTKFsENAil9eLQ6stLc-Lx3xgJbi-Y2wvm9oK5Z8H0X-Hchzw
CitedBy_id crossref_primary_10_1016_j_yao_2021_02_022
crossref_primary_10_34172_apb_2023_079
crossref_primary_10_1007_s11886_023_01909_3
crossref_primary_10_1166_jbt_2022_2947
crossref_primary_10_3389_fgene_2020_591667
crossref_primary_10_3389_fonc_2022_867670
crossref_primary_10_1007_s12032_021_01537_3
crossref_primary_10_1080_02656736_2024_2335201
crossref_primary_10_1038_s41598_022_17460_0
crossref_primary_10_3390_jof6040367
crossref_primary_10_1016_j_apradiso_2021_109838
crossref_primary_10_1038_s41598_023_45984_6
crossref_primary_10_1016_j_ejphar_2022_175421
crossref_primary_10_2967_jnumed_121_262270
crossref_primary_10_1186_s40658_023_00558_3
Cites_doi 10.1002/pros.2990180305
10.1053/ctrv.2000.0210
10.1146/annurev-med-051517-011947
10.2967/jnumed.115.171397
10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S
10.1007/s00259-017-3751-z
10.2967/jnumed.118.219592
10.1093/annonc/mdy434.011
10.1016/j.juro.2010.03.034
10.1111/j.1440-1827.2008.02294.x
10.1007/s00259-017-3848-4
10.1634/theoncologist.2020-0028
10.4103/1450-1147.89780
10.1016/0167-0115(83)90281-1
10.1186/s12885-019-5297-x
10.2214/AJR.18.20845
10.2967/jnumed.117.198192
10.1038/aja.2011.164
10.18632/oncotarget.21600
10.1097/PPO.0b013e31827f123e
10.1146/annurev-med-062117-073027
10.2967/jnumed.116.183194
10.1007/s00259-017-3702-8
10.1007/s00109-015-1329-4
10.1158/1078-0432.CCR-11-1357
10.1200/JCO.2004.09.154
10.1007/s00259-014-2713-y
10.2967/jnumed.118.208785
10.1200/JCO.2019.37.7_suppl.232
10.1089/cbr.2019.3308
10.1016/j.juro.2013.10.041
10.3322/caac.21442
10.1007/s00259-014-2830-7
10.1186/s13550-019-0488-7
10.1007/s12149-019-01404-2
10.1007/s00259-016-3481-7
10.1007/s00259-017-3716-2
10.7150/thno.20586
10.1016/1078-1439(95)00002-Y
10.2967/jnumed.116.178228
10.1097/01.ju.0000091655.77601.0c
10.1016/j.eucr.2017.11.021
10.1200/JCO.2005.05.160
10.1007/s00259-018-4167-0
10.1007/s11307-015-0850-8
10.1016/j.drudis.2014.07.008
10.1186/s40644-019-0211-y
10.2967/jnumed.116.173757
10.1158/1078-0432.CCR-10-3120
10.1016/j.ijrobp.2019.08.031
10.2967/jnumed.116.178673
10.1038/316823a0
10.1016/j.ijrobp.2019.06.2259
10.1002/cncr.32072
10.1001/jamaoncol.2017.3588
10.1038/onc.2014.115
10.1016/j.peptides.2015.04.026
10.1007/s00259-005-1764-5
10.2967/jnumed.118.223099
10.1016/S0022-5347(05)64820-3
10.1200/jco.2016.34.2_suppl.80
10.2174/092986712799034888
10.1259/bjr.20160748
10.1158/1078-0432.CCR-05-0826
10.1186/s40658-020-0286-3
10.1038/nrc2351
10.1016/S0140-6736(10)60172-9
10.1007/s12253-008-9104-2
10.1016/S0090-4295(99)00314-3
10.1016/j.euo.2018.08.011
10.1002/(SICI)1097-0142(19980815)83:4<739::AID-CNCR16>3.0.CO;2-T
10.2967/jnumed.119.226381
10.1200/JCO.2013.50.1684
10.1007/s00259-018-4220-z
10.1007/s00259-017-3657-9
10.1016/j.ijrobp.2019.03.014
10.1158/1078-0432.CCR-15-0552
10.7150/thno.37894
10.1056/NEJMoa1213755
10.1007/s12149-017-1224-x
10.1007/s10555-013-9471-3
10.1124/pr.107.07108
10.1053/hp.2000.6698
10.2967/jnumed.117.203539
10.1158/1078-0432.CCR-13-0231
ContentType Journal Article
Copyright Copyright © 2020 Abou, Benabdallah, Jiang, Peng, Zhang, Villmer, Longtine and Thorek. 2020 Abou, Benabdallah, Jiang, Peng, Zhang, Villmer, Longtine and Thorek
Copyright_xml – notice: Copyright © 2020 Abou, Benabdallah, Jiang, Peng, Zhang, Villmer, Longtine and Thorek. 2020 Abou, Benabdallah, Jiang, Peng, Zhang, Villmer, Longtine and Thorek
DBID AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fonc.2020.00884
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2234-943X
EndPage 884
ExternalDocumentID oai_doaj_org_article_8e08460ed5554000a202be14611b4501
10_3389_fonc_2020_00884
GrantInformation_xml – fundername: National Institutes of Health
– fundername: American Cancer Society
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EJD
EMOBN
GROUPED_DOAJ
GX1
HYE
IAO
IEA
IHR
IHW
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
7X8
5PM
ID FETCH-LOGICAL-c436t-a90f0b7d07441f932aa3db3088f6d29c77c826b02c8238480a1ae46e4a0f61fe3
IEDL.DBID RPM
ISSN 2234-943X
IngestDate Tue Oct 22 15:09:51 EDT 2024
Tue Sep 17 20:54:08 EDT 2024
Fri Oct 25 22:29:25 EDT 2024
Thu Sep 26 16:24:32 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c436t-a90f0b7d07441f932aa3db3088f6d29c77c826b02c8238480a1ae46e4a0f61fe3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
This article was submitted to Cancer Imaging and Image-directed Interventions, a section of the journal Frontiers in Oncology
Edited by: Georgios S. Limouris, National and Kapodistrian University of Athens, Greece
Reviewed by: Di Dong, Institute of Automation (CAS), China; Caroline Rousseau, Institut de Cancérologie de l'Ouest (ICO), France
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290246/
PMID 32582550
PQID 2417404640
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_8e08460ed5554000a202be14611b4501
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7290246
proquest_miscellaneous_2417404640
crossref_primary_10_3389_fonc_2020_00884
PublicationCentury 2000
PublicationDate 2020-06-05
PublicationDateYYYYMMDD 2020-06-05
PublicationDate_xml – month: 06
  year: 2020
  text: 2020-06-05
  day: 05
PublicationDecade 2020
PublicationTitle Frontiers in oncology
PublicationYear 2020
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Huggins (B10) 2002; 168
Larimer (B17) 2018; 59
Iagaru (B87) 2017; 58
Rahbar (B54) 2017; 58
Ferraldeschi (B12) 2015; 34
Mannweiler (B28) 2009; 15
Bander (B35) 2003; 170
Wieser (B86) 2017; 44
Penman (B79) 1983; 7
Ramos-Álvarez (B82) 2015; 72
Emmett (B41) 2019; 60
Lilja (B6) 2008; 8
Jensen (B80) 2008; 60
Huggins (B9) 1941; 1
Carver (B8) 2014; 19
Ren (B89) 2015; 93
Kratochwil (B60) 2016; 57
Milowsky (B62) 2004; 22
Lim (B74) 2019; 105
Dehdashti (B20) 2005; 32
Hinkle (B32) 1998; 83
Rousseau (B42) 2019; 60
Mehra (B5) 2011; 17
Phillips (B52) 2018; 16
Fox (B22) 2018; 4
McCarthy (B44) 2019; 104
Ferreira (B49) 2019; 19
Wright (B25) 1995; 1
Bubendorf (B3) 2000; 31
Rowe (B37) 2019; 70
Kratochwil (B71) 2016; 57
Niaz (B77) 2020
Yadav (B63) 2017; 44
Larson (B21) 2004; 45
Rahbar (B65) 2018; 45
Morris (B36) 2005; 11
Sunday (B78) 1989
Rajpar (B4) 2013; 19
Tagawa (B59) 2013; 19
Calais (B43) 2019; 19
Miederer (B19) 2004; 45
Parker (B90) 2013; 369
Barinka (B29) 2012; 19
Plouznikoff (B51) 2019; 33
Touijer (B83) 2019; 2
Bander (B61) 2005; 23
Hoving (B23) 2019; 37
Benabdallah (B93) 2019; 9
Yadav (B70) 2019; 213
Cuttitta (B81) 1985; 316
Manyak (B33) 1999; 54
Ahmadzadehfar (B67) 2017; 44
Flux (B91) 2017; 90
Eppard (B47) 2017; 7
Siegel (B1) 2018; 68
Wynant (B31) 1991; 18
Zechmann (B56) 2014; 41
Bräuer (B69) 2017; 44
Umeda (B94) 2018; 32
Kratochwil (B58) 2018; 59
Sathekge (B57) 2017; 44
Szabo (B40) 2015; 17
Chen (B45) 2011; 17
Bonasera (B18) 1996; 37
Kusumi (B27) 2008; 58
Sathekge (B72) 2019; 46
Phillips (B53) 2019; 105
Scher (B16) 2010; 375
Rathkopf (B24) 2013; 31
Roivainen (B84) 2012
Nørgaard (B2) 2010; 184
Pedersen (B15) 2012; 14
Tagawa (B76) 2019; 125
Pfitzenmaier (B13) 2007
Werner (B48) 2020; 10
Bostwick (B26) 1998; 82
Abou (B92) 2020
Coleman (B88) 2001; 27
Ferdinandus (B66) 2017; 58
Koivisto (B14) 1997; 57
Pandit-Taskar (B39) 2015; 21
Rosar (B46) 2020; 7
Horoszewicz (B30) 1987; 7
Teo (B11) 2019; 70
Kelly (B55) 2019; 60
Loke (B75) 2011; 10
dos Santos (B73) 2019; 46
Stephens (B85) 2016; 34
Siva (B50) 2018; 29
Ahmadzadehfar (B68) 2017; 8
Osborne (B34) 2014; 191
Rahbar (B64) 2016; 57
Augello (B7) 2014; 33
Pandit-Taskar (B38) 2014; 41
References_xml – volume: 18
  start-page: 229
  year: 1991
  ident: B31
  article-title: Immunoscintigraphy of prostatic cancer: preliminary results with 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356)
  publication-title: Prostate
  doi: 10.1002/pros.2990180305
  contributor:
    fullname: Wynant
– volume: 27
  start-page: 165
  year: 2001
  ident: B88
  article-title: Metastatic bone disease: clinical features, pathophysiology and treatment strategies
  publication-title: Cancer Treat Rev
  doi: 10.1053/ctrv.2000.0210
  contributor:
    fullname: Coleman
– volume: 70
  start-page: 479
  year: 2019
  ident: B11
  article-title: Treatment of advanced prostate cancer
  publication-title: Annu Rev Med
  doi: 10.1146/annurev-med-051517-011947
  contributor:
    fullname: Teo
– volume: 57
  start-page: 1170
  year: 2016
  ident: B60
  article-title: PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.115.171397
  contributor:
    fullname: Kratochwil
– volume: 82
  start-page: 2256
  year: 1998
  ident: B26
  article-title: Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases
  publication-title: Cancer
  doi: 10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S
  contributor:
    fullname: Bostwick
– volume: 44
  start-page: 1663
  year: 2017
  ident: B69
  article-title: 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-017-3751-z
  contributor:
    fullname: Bräuer
– volume: 60
  start-page: 649
  year: 2019
  ident: B55
  article-title: A single dose of 225Ac-RPS-074 induces a complete tumor response in an LNCaP xenograft model
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.118.219592
  contributor:
    fullname: Kelly
– volume: 29
  start-page: mdy434
  year: 2018
  ident: B50
  article-title: 223P Using PSMA PET/CT to assess response in metastatic prostate cancer (mPC) patients (pts) receiving upfront chemohormonal therapy
  publication-title: Ann Oncol.
  doi: 10.1093/annonc/mdy434.011
  contributor:
    fullname: Siva
– volume: 184
  start-page: 162
  year: 2010
  ident: B2
  article-title: Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007)
  publication-title: J Urol
  doi: 10.1016/j.juro.2010.03.034
  contributor:
    fullname: Nørgaard
– volume: 58
  start-page: 687
  year: 2008
  ident: B27
  article-title: Immunohistochemical detection of carcinoma in radical prostatectomy specimens following hormone therapy
  publication-title: Pathol Int
  doi: 10.1111/j.1440-1827.2008.02294.x
  contributor:
    fullname: Kusumi
– volume: 45
  start-page: 12
  year: 2018
  ident: B65
  article-title: PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-017-3848-4
  contributor:
    fullname: Rahbar
– start-page: 2020
  year: 2020
  ident: B77
  article-title: Pilot study of hyperfractionated dosing of lutetium-177-labeled antiprostate-specific membrane antigen monoclonal antibody J591 (177 Lu-J591) for metastatic castration-resistant prostate cancer
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2020-0028
  contributor:
    fullname: Niaz
– volume: 57
  start-page: 314
  year: 1997
  ident: B14
  article-title: Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer
  publication-title: Cancer Res
  contributor:
    fullname: Koivisto
– volume: 10
  start-page: 122
  year: 2011
  ident: B75
  article-title: Dosimetric considerations in radioimmunotherapy and systemic radionuclide therapies: a review
  publication-title: World J Nucl Med
  doi: 10.4103/1450-1147.89780
  contributor:
    fullname: Loke
– volume: 7
  start-page: 53
  year: 1983
  ident: B79
  article-title: Distribution and characterisation of immunoreactive somatostatin in human gastrointestinal tract
  publication-title: Regul Pept
  doi: 10.1016/0167-0115(83)90281-1
  contributor:
    fullname: Penman
– volume: 19
  start-page: 18
  year: 2019
  ident: B43
  article-title: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
  publication-title: BMC Cancer
  doi: 10.1186/s12885-019-5297-x
  contributor:
    fullname: Calais
– volume: 213
  start-page: 275
  year: 2019
  ident: B70
  article-title: Radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis
  publication-title: AJR Am J Roentgenol
  doi: 10.2214/AJR.18.20845
  contributor:
    fullname: Yadav
– volume: 58
  start-page: 1883
  year: 2017
  ident: B87
  article-title: Will GRPR compete with PSMA as a target in prostate cancer?
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.117.198192
  contributor:
    fullname: Iagaru
– volume: 14
  start-page: 423
  year: 2012
  ident: B15
  article-title: The prostate cancer bone marrow niche: more than just “fertile soil”
  publication-title: Asian J Androl
  doi: 10.1038/aja.2011.164
  contributor:
    fullname: Pedersen
– volume: 8
  start-page: 103108
  year: 2017
  ident: B68
  article-title: Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.21600
  contributor:
    fullname: Ahmadzadehfar
– volume: 19
  start-page: 66
  year: 2013
  ident: B4
  article-title: Bone targeted therapies in metastatic castration-resistant prostate cancer
  publication-title: Cancer J
  doi: 10.1097/PPO.0b013e31827f123e
  contributor:
    fullname: Rajpar
– volume-title: Urologic Oncology: Seminars and Original Investigations
  year: 2007
  ident: B13
  article-title: The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: a comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer
  contributor:
    fullname: Pfitzenmaier
– volume: 70
  start-page: 461
  year: 2019
  ident: B37
  article-title: Imaging of prostate-specific membrane antigen with small-molecule PET radiotracers: from the bench to advanced clinical applications
  publication-title: Annu Rev Med
  doi: 10.1146/annurev-med-062117-073027
  contributor:
    fullname: Rowe
– volume: 58
  start-page: 85
  year: 2017
  ident: B54
  article-title: German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.116.183194
  contributor:
    fullname: Rahbar
– volume: 44
  start-page: 1463
  year: 2017
  ident: B86
  article-title: Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68 Ga-RM2: Preliminary results in patients with negative or inconclusive [18 F] Fluoroethylcholine-PET/CT
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-017-3702-8
  contributor:
    fullname: Wieser
– volume: 93
  start-page: 1203
  year: 2015
  ident: B89
  article-title: Bone metastasis and the metastatic niche
  publication-title: J Mol Med
  doi: 10.1007/s00109-015-1329-4
  contributor:
    fullname: Ren
– volume: 17
  start-page: 7645
  year: 2011
  ident: B45
  article-title: 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-11-1357
  contributor:
    fullname: Chen
– volume: 22
  start-page: 2522
  year: 2004
  ident: B62
  article-title: Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2004.09.154
  contributor:
    fullname: Milowsky
– volume: 41
  start-page: 1280
  year: 2014
  ident: B56
  article-title: Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-014-2713-y
  contributor:
    fullname: Zechmann
– start-page: 54
  volume-title: Pathology Reviews.
  year: 1989
  ident: B78
  article-title: Gastrin-releasing peptide (mammalian bombesin) gene expression in health and disease
  contributor:
    fullname: Sunday
– start-page: 10013
  volume-title: European Journal Of Nuclear Medicine And Molecular Imaging
  year: 2012
  ident: B84
  article-title: Radiometabolism, whole-body distribution and radiation dosimetry of Ga-68-bombesin antagonist BAY86-7548 in healthy men
  contributor:
    fullname: Roivainen
– volume: 45
  start-page: 129
  year: 2004
  ident: B19
  article-title: Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates
  publication-title: J Nucl Med
  contributor:
    fullname: Miederer
– volume: 59
  start-page: 1538
  year: 2018
  ident: B17
  article-title: Specific 18F-FDHT accumulation in human prostate cancer xenograft murine models is facilitated by prebinding to sex hormone-binding globulin
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.118.208785
  contributor:
    fullname: Larimer
– volume: 37
  start-page: 232
  year: 2019
  ident: B23
  article-title: Early 18F-FDHT PET/CT as a predictor of treatment response in mCRPC treated with enzalutamide
  publication-title: J Clin Orthod
  doi: 10.1200/JCO.2019.37.7_suppl.232
  contributor:
    fullname: Hoving
– year: 2020
  ident: B92
  article-title: Preclinical single photon emission computed tomography of alpha particle-emitting radium-223
  publication-title: Cancer Biother Radiopharm.
  doi: 10.1089/cbr.2019.3308
  contributor:
    fullname: Abou
– volume: 191
  start-page: 1439
  year: 2014
  ident: B34
  article-title: A Prospective pilot study of 89Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy
  publication-title: J Urol
  doi: 10.1016/j.juro.2013.10.041
  contributor:
    fullname: Osborne
– volume: 68
  start-page: 7
  year: 2018
  ident: B1
  article-title: Cancer statistics, 2018
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21442
  contributor:
    fullname: Siegel
– volume: 41
  start-page: 2093
  year: 2014
  ident: B38
  article-title: 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-014-2830-7
  contributor:
    fullname: Pandit-Taskar
– volume: 9
  start-page: 20
  year: 2019
  ident: B93
  article-title: 223Ra-dichloride therapy of bone metastasis: optimization of SPECT images for quantification
  publication-title: EJNMMI Res
  doi: 10.1186/s13550-019-0488-7
  contributor:
    fullname: Benabdallah
– volume: 33
  start-page: 945
  year: 2019
  ident: B51
  article-title: Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients
  publication-title: Ann Nucl Med
  doi: 10.1007/s12149-019-01404-2
  contributor:
    fullname: Plouznikoff
– volume: 44
  start-page: 81
  year: 2017
  ident: B63
  article-title: 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-016-3481-7
  contributor:
    fullname: Yadav
– volume: 44
  start-page: 1448
  year: 2017
  ident: B67
  article-title: Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-017-3716-2
  contributor:
    fullname: Ahmadzadehfar
– volume: 7
  start-page: 4359
  year: 2017
  ident: B47
  article-title: Clinical translation and first in-human use of [44Sc]Sc-PSMA-617 for PET imaging of metastasized castrate-resistant prostate cancer
  publication-title: Theranostics
  doi: 10.7150/thno.20586
  contributor:
    fullname: Eppard
– volume: 1
  start-page: 18
  year: 1995
  ident: B25
  article-title: Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues
  publication-title: Urol Oncol
  doi: 10.1016/1078-1439(95)00002-Y
  contributor:
    fullname: Wright
– volume: 58
  start-page: 312
  year: 2017
  ident: B66
  article-title: Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.116.178228
  contributor:
    fullname: Ferdinandus
– volume: 170
  start-page: 1717
  year: 2003
  ident: B35
  article-title: Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen
  publication-title: J Urol
  doi: 10.1097/01.ju.0000091655.77601.0c
  contributor:
    fullname: Bander
– volume: 16
  start-page: 86
  year: 2018
  ident: B52
  article-title: Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by 18F-DCFPyL PET/CT
  publication-title: Urol Case Rep
  doi: 10.1016/j.eucr.2017.11.021
  contributor:
    fullname: Phillips
– volume: 23
  start-page: 4591
  year: 2005
  ident: B61
  article-title: Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.05.160
  contributor:
    fullname: Bander
– volume: 1
  start-page: 293
  year: 1941
  ident: B9
  article-title: Studies on prostatic cancer
  publication-title: Cancer Res
  contributor:
    fullname: Huggins
– volume: 46
  start-page: 129
  year: 2019
  ident: B72
  article-title: 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-018-4167-0
  contributor:
    fullname: Sathekge
– volume: 17
  start-page: 565
  year: 2015
  ident: B40
  article-title: Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer
  publication-title: Mol Imaging Biol
  doi: 10.1007/s11307-015-0850-8
  contributor:
    fullname: Szabo
– volume: 19
  start-page: 1493
  year: 2014
  ident: B8
  article-title: Strategies for targeting the androgen receptor axis in prostate cancer
  publication-title: Drug Discov Today
  doi: 10.1016/j.drudis.2014.07.008
  contributor:
    fullname: Carver
– volume: 19
  start-page: 23
  year: 2019
  ident: B49
  article-title: Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution
  publication-title: Cancer Imaging
  doi: 10.1186/s40644-019-0211-y
  contributor:
    fullname: Ferreira
– volume: 57
  start-page: 1334
  year: 2016
  ident: B64
  article-title: Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.116.173757
  contributor:
    fullname: Rahbar
– volume: 17
  start-page: 3924
  year: 2011
  ident: B5
  article-title: Characterization of bone metastases from rapid autopsies of prostate cancer patients
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-10-3120
  contributor:
    fullname: Mehra
– volume: 105
  start-page: 681
  year: 2019
  ident: B53
  article-title: Primary outcomes of a phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE)
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2019.08.031
  contributor:
    fullname: Phillips
– volume: 57
  start-page: 1941
  year: 2016
  ident: B71
  article-title: 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.116.178673
  contributor:
    fullname: Kratochwil
– volume: 316
  start-page: 823
  year: 1985
  ident: B81
  article-title: Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer
  publication-title: Nature
  doi: 10.1038/316823a0
  contributor:
    fullname: Cuttitta
– volume: 105
  start-page: E130
  year: 2019
  ident: B74
  article-title: Predicting radiation-adverse effects using three-dimensional dose and fractionation data: radiation dermatitis
  publication-title: Int J Radiat Oncol Biol Phys.
  doi: 10.1016/j.ijrobp.2019.06.2259
  contributor:
    fullname: Lim
– volume: 125
  start-page: 2561
  year: 2019
  ident: B76
  article-title: Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177 Lu-J591) for metastatic castration-resistant prostate cancer
  publication-title: Cancer
  doi: 10.1002/cncr.32072
  contributor:
    fullname: Tagawa
– volume: 4
  start-page: 217
  year: 2018
  ident: B22
  article-title: Positron emission tomography/computed tomography-based assessments of androgen receptor expression and glycolytic activity as a prognostic biomarker for metastatic castration-resistant prostate cancer
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2017.3588
  contributor:
    fullname: Fox
– volume: 34
  start-page: 1745
  year: 2015
  ident: B12
  article-title: Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects
  publication-title: Oncogene
  doi: 10.1038/onc.2014.115
  contributor:
    fullname: Ferraldeschi
– volume: 72
  start-page: 128
  year: 2015
  ident: B82
  article-title: Insights into bombesin receptors and ligands: highlighting recent advances
  publication-title: Peptides
  doi: 10.1016/j.peptides.2015.04.026
  contributor:
    fullname: Ramos-Álvarez
– volume: 32
  start-page: 344
  year: 2005
  ident: B20
  article-title: Positron tomographic assessment of androgen receptors in prostatic carcinoma
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-005-1764-5
  contributor:
    fullname: Dehdashti
– volume: 60
  start-page: 950
  year: 2019
  ident: B41
  article-title: Rapid modulation of PSMA expression by androgen deprivation: serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.118.223099
  contributor:
    fullname: Emmett
– volume: 168
  start-page: 9
  year: 2002
  ident: B10
  article-title: Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
  publication-title: J Urol
  doi: 10.1016/S0022-5347(05)64820-3
  contributor:
    fullname: Huggins
– volume: 34
  start-page: 80
  year: 2016
  ident: B85
  article-title: Detection of prostate cancer with the [68Ga]-labeled bombesin antagonist RM2 in patients undergoing radical prostatectomy
  publication-title: J Clin Oncol.
  doi: 10.1200/jco.2016.34.2_suppl.80
  contributor:
    fullname: Stephens
– volume: 19
  start-page: 856
  year: 2012
  ident: B29
  article-title: Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer
  publication-title: Curr Med Chem
  doi: 10.2174/092986712799034888
  contributor:
    fullname: Barinka
– volume: 7
  start-page: 927
  year: 1987
  ident: B30
  article-title: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
  publication-title: Anticancer Res
  contributor:
    fullname: Horoszewicz
– volume: 90
  start-page: 20160748
  year: 2017
  ident: B91
  article-title: Imaging and dosimetry for radium-223: the potential for personalized treatment
  publication-title: Br J Radiol
  doi: 10.1259/bjr.20160748
  contributor:
    fullname: Flux
– volume: 11
  start-page: 7454
  year: 2005
  ident: B36
  article-title: Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-05-0826
  contributor:
    fullname: Morris
– volume: 7
  start-page: 16
  year: 2020
  ident: B46
  article-title: Image quality analysis of 44Sc on two preclinical PET scanners: a comparison to 68Ga
  publication-title: EJNMMI Phys
  doi: 10.1186/s40658-020-0286-3
  contributor:
    fullname: Rosar
– volume: 8
  start-page: 268
  year: 2008
  ident: B6
  article-title: Prostate-specific antigen and prostate cancer: prediction, detection and monitoring
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2351
  contributor:
    fullname: Lilja
– volume: 375
  start-page: 1437
  year: 2010
  ident: B16
  article-title: Prostate cancer foundation/department of defense prostate cancer clinical trials consortium. antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(10)60172-9
  contributor:
    fullname: Scher
– volume: 15
  start-page: 167
  year: 2009
  ident: B28
  article-title: Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis
  publication-title: Pathol Oncol Res
  doi: 10.1007/s12253-008-9104-2
  contributor:
    fullname: Mannweiler
– volume: 54
  start-page: 1058
  year: 1999
  ident: B33
  article-title: Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer
  publication-title: Urology
  doi: 10.1016/S0090-4295(99)00314-3
  contributor:
    fullname: Manyak
– volume: 2
  start-page: 166
  year: 2019
  ident: B83
  article-title: Prospective study of the radiolabeled GRPR antagonist BAY86-7548 for positron emission tomography/computed tomography imaging of newly diagnosed prostate cancer
  publication-title: Eur Urol Oncol
  doi: 10.1016/j.euo.2018.08.011
  contributor:
    fullname: Touijer
– volume: 37
  start-page: 1009
  year: 1996
  ident: B18
  article-title: Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons
  publication-title: J Nucl Med
  contributor:
    fullname: Bonasera
– volume: 83
  start-page: 739
  year: 1998
  ident: B32
  article-title: Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide
  publication-title: Cancer: Interdiscipl Int J Am Cancer Soc
  doi: 10.1002/(SICI)1097-0142(19980815)83:4<739::AID-CNCR16>3.0.CO;2-T
  contributor:
    fullname: Hinkle
– volume: 60
  start-page: 1587
  year: 2019
  ident: B42
  article-title: A prospective study on 18F-DCFPyL PSMA PET/CT imaging in biochemical recurrence of prostate cancer
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.119.226381
  contributor:
    fullname: Rousseau
– volume: 31
  start-page: 3525
  year: 2013
  ident: B24
  article-title: Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2013.50.1684
  contributor:
    fullname: Rathkopf
– volume: 46
  start-page: 1081
  year: 2019
  ident: B73
  article-title: Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-018-4220-z
  contributor:
    fullname: dos Santos
– volume: 44
  start-page: 1099
  year: 2017
  ident: B57
  article-title: 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-017-3657-9
  contributor:
    fullname: Sathekge
– volume: 45
  start-page: 366
  year: 2004
  ident: B21
  article-title: Tumor localization of 16β-18F-fluoro-5α-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer
  publication-title: J Nucl Med
  contributor:
    fullname: Larson
– volume: 104
  start-page: 801
  year: 2019
  ident: B44
  article-title: A multicenter prospective clinical trial of 68gallium PSMA HBED-CC PET-CT restaging in biochemically relapsed prostate carcinoma: oligometastatic rate and distribution compared with standard imaging
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2019.03.014
  contributor:
    fullname: McCarthy
– volume: 21
  start-page: 5277
  year: 2015
  ident: B39
  article-title: A phase I/II study for analytic validation of 89Zr-J591 immunoPET as a molecular imaging agent for metastatic prostate cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-0552
  contributor:
    fullname: Pandit-Taskar
– volume: 10
  start-page: 1
  year: 2020
  ident: B48
  article-title: 18F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging
  publication-title: Theranostics
  doi: 10.7150/thno.37894
  contributor:
    fullname: Werner
– volume: 369
  start-page: 213
  year: 2013
  ident: B90
  article-title: Alpha emitter radium-223 and survival in metastatic prostate cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1213755
  contributor:
    fullname: Parker
– volume: 32
  start-page: 105
  year: 2018
  ident: B94
  article-title: Evaluation of bone metastatic burden by bone SPECT/CT in metastatic prostate cancer patients: defining threshold value for total bone uptake and assessment in radium-223 treated patients
  publication-title: Ann Nucl Med
  doi: 10.1007/s12149-017-1224-x
  contributor:
    fullname: Umeda
– volume: 33
  start-page: 399
  year: 2014
  ident: B7
  article-title: AR function in promoting metastatic prostate cancer
  publication-title: Cancer Metastasis Rev
  doi: 10.1007/s10555-013-9471-3
  contributor:
    fullname: Augello
– volume: 60
  start-page: 1
  year: 2008
  ident: B80
  article-title: International union of pharmacology
  publication-title: Pharmacol Rev
  doi: 10.1124/pr.107.07108
  contributor:
    fullname: Jensen
– volume: 31
  start-page: 578
  year: 2000
  ident: B3
  article-title: Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients
  publication-title: Hum Pathol
  doi: 10.1053/hp.2000.6698
  contributor:
    fullname: Bubendorf
– volume: 59
  start-page: 795
  year: 2018
  ident: B58
  article-title: Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.117.203539
  contributor:
    fullname: Kratochwil
– volume: 19
  start-page: 5182
  year: 2013
  ident: B59
  article-title: Phase II study of lutetium-177–labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-13-0231
  contributor:
    fullname: Tagawa
SSID ssj0000650103
Score 2.353725
SecondaryResourceType review_article
Snippet Metastatic prostate cancer is incurable, and novel methods to detect the disease earlier and to direct definitive treatment are needed. Molecularly specific...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
StartPage 884
SubjectTerms alpha particle
Oncology
peptide
prostate cancer
radionuclide
radiotherapy
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NS8MwFA-yg3gRP7F-UcGDCGFpkzbtcQ7HEKYeNtgtJE2CXjKZm_77vtd2sp68eCq0pU1-7yXvPd7L7xFyy6yUWcYtNal3VHieUVOYilqBeT7QqbzEs8OT53w8E0_zbL7V6gtrwhp64Aa4fuEYmEjmbAaGD9avhmjdOOxGnRj4WBP4sHQrmGr24AwbGDRcPhCFlX2_CMhYmGIlV1GIjhmq2fo7Lma3QHLL4owOyH7rKsaDZoiHZMeFI7I7aZPhx-T-FU9sgK8YD1F0y3iKZ6nComZejmk8CPHLF24F7vuEzEaP0-GYtq0PaCV4vqK6ZJ4ZacHAi8SDj6U1t4bDyH1u07KSsoK4wLAULrwQBdOJdiJ3QjOfJ97xU9ILi-DOSOyq1KdMO884hwVaGqErawsvNXgbrEoicrdBQn00DBcKIgMETSFoCkFTNWgReUCkfl9Daur6BghMtQJTfwksIjcbnBWoMuYndHCL9acCZ0IKTLWyiMiOADp_7D4J7281KTYECaBd-fl_DPGC7OGk64qw7JL0Vsu1uwLfY2WuazX7ATqc0_0
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA66gngRn7i-qOBBhGrapK-DyLq4LMKqh13YW0iaRAVptbvr498703bVgkdPhbYh7TeTzDfMZIaQY6qjKAiYdpVvjcstC1wVq9TVHON8oFNhgmeHB7dhf8RvxsH4px1QDeDkT9cO-0mNiuezj9fPS1jwF-hxgr09t3mGxQh9TNKKY75Ilnwwi5jfNai5frUtB9jToCrv89e4hmUqC_g3WGczZ_KXEeqtkdWaPTqdStzrZMFkG2R5UMfHN8npPR7iAProdFGahTPE41VZXhZjdlynkzl3b7g7mPctMupdD7t9t-6G4KachVNXJtRSFWmw-dyzQLukZFox-HIbaj9JoygFV0FRHy4s5jGVnjQ8NFxSG3rWsG3SyvLM7BDHpL71qTSWMgZrNlFcplrHNpJAQGjqtcnJHAnxUhW9EOAsIGgCQRMImihBa5MrROr7NaxWXd7IiwdRK7-IDQWaQ40OgLyAJCSMVwY7insKFALmO5rjLEC7MWQhM5PPJgL4RcQx-krbJGoIoDFj80n29FjWyQa_ARQu3P2PT9wjK_jTZZJYsE9a02JmDoCOTNVhqWZfEnjcwA
  priority: 102
  providerName: Scholars Portal
Title Prostate Cancer Theranostics - An Overview
URI https://search.proquest.com/docview/2417404640
https://pubmed.ncbi.nlm.nih.gov/PMC7290246
https://doaj.org/article/8e08460ed5554000a202be14611b4501
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEA7qQbyIT1xfVPAgQt20Sfo46uIDYdWDwt5CnipoKuuqf9-ZbFe2Vy8ptE3TzEw73zAvQo6pLUshmE117l3KPROprrRJLUc_H8hUUWPu8PCuuHnityMxWiBilgsTg_aNfj0Lb-9n4fUlxlZ-vJv-LE6s_zAcACCEJxX9RbII6nfORJ_-fgX2LpiW8QEDrO77JmCxwhyDuKoKO_GwXIBlhLn2c8oo1uzvAM1umOSc3rlaI6stYEzOpy-2ThZc2CDLw9YlvklOHzBvAxBjMkAGjpNHzKgKTay_nKTJeUjuv_GH4H62yNPV5ePgJm0bIKSGs2KSqpp6qksLap5nHpCWUsxqBpvwhc1rU5YGrANNcziwildUZcrxwnFFfZF5x7bJUmiC2yGJM7nPqXKeMgafaa25MtZWvlSAOajJeuRkRgn5Ma1zIcE-QPpJpJ9E-slIvx65QEr93YYFquOJZvwsWzbJylFANtRZAXgFmKJgvnbYRDzTIAOw3tGMzhIEGr0UKrjm61MCpCg5Olxpj5QdBnRW7F4BSYmlsVvJ2P33zD2ygjuNwWBinyxNxl_uAGDHRB9Gcx3G61EG45BXh1HwfgFrgNlB
link.rule.ids 230,314,727,780,784,864,885,2102,24318,27924,27925,53791,53793
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgEXxFNseQWJA0JK14ntODmWFdUC3dLDVurN8hMqUadatuXvM-PNos2VU6QkTuJvJvY3mhfAe-aVkpL70tYxlCJyWdrWutIL8vOhTjUd5Q4vTpv5ufh6IS_2QG5zYXLQvrOXh-nX1WG6_JljK6-v3HQbJzY9W8yQEOKTmukduCu56qodI32zAEvqXrAp5IMmWDeNfaJyhTWFcbUt9eLhtUTbiLLtd7ajXLV_RDXHgZI7O8_xI3g4UMbiaPNpj2EvpCdwbzE4xZ_CxzPK3EDOWMxIhKtiSTlVqc8VmIuyOErF91taEsKfZ3B-_Hk5m5dDC4TSCd6sS9OxyKzyuNGLKiLXMoZ7y3ESsfF155RyaB9YVuOBt6JlpjJBNEEYFpsqBv4c9lOfwgsogqtjzUyIjHP8UTsrjPO-jcog62CumsCHLRL6elPpQqOFQPhpwk8TfjrjN4FPhNS_26hEdT7Rr37oQVC6DQy5DQteImNBoRgcbwO1Ea8sagG-790WZ40qTX4Kk0J_81sjqVCCXK5sAmokgNEbx1dQV3Jx7EE3Dv575Fu4P18uTvTJl9NvL-EBzTqHhslXsL9e3YTXSELW9k1Wub-1_NnW
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwELYoSIhLVV5i-4BU4oAqhTixnccRFla0ZekeQOJm-QlI4Ky2S_v3O-PNos21p0hJnMTfTOxvNC9CjqmtKiGYTXXhXco9E6mutUktRz8f6FTZYO7w-Ka8uuM_7sX9SquvGLRv9NNpeH45DU-PMbZy-mKyZZxYNhkPgRDCk8psan32jmwIBkq2YqgvFmGBHQwWxXzADGsy3wYsWVhgKFddYz8eVgiwjzDjfmVLipX7e3SzHyy5svuMPpD3HW1Mzhaft03WXNghm-POMb5Lvk0wewN4YzJEMc6SW8yrCm2swpykyVlIfv3BZcH93SN3o8vb4VXatUFIDWflPFUN9VRXFjZ7nnvgW0oxqxlMwpe2aExVGbARNC3gwGpeU5Urx0vHFfVl7h3bJ-uhDe6AJM4UvqDKecoY_KyN5spYW_tKAfOgJh-QkyUScrqodiHBSkD8JOInET8Z8RuQc0Tq7TYsUx1PtLMH2QlL1o4Cv6HOCmAtIBQF47XDVuK5Bk2A931d4ixBrdFXoYJrX39LIBYVR7crHZCqJ4DeG_tXQF9igexOPz7-98gjsjm5GMnr7zc_P5EtnHSMDhOfyfp89uq-AA-Z68Oocf8A6vfa6Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prostate+Cancer+Theranostics+-+An+Overview&rft.jtitle=Frontiers+in+oncology&rft.au=Diane+Abou&rft.au=Diane+Abou&rft.au=Diane+Abou&rft.au=Nadia+Benabdallah&rft.date=2020-06-05&rft.pub=Frontiers+Media+S.A&rft.eissn=2234-943X&rft.volume=10&rft_id=info:doi/10.3389%2Ffonc.2020.00884&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_8e08460ed5554000a202be14611b4501
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon